

**Next Day Disclosure Return***(Equity issuer - changes in issued share capital and/or share buybacks)*

Name of listed issuer: Wenzhou Kangning Hospital Co., Ltd.

Stock code: 2120

Date submitted: 16 April 2020

*Section I must be completed by a listed issuer where there has been a change in its issued share capital which is discloseable pursuant to rule 13.25A of the Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Exchange”).*

*Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under rule 10.06(4)(a).*

**Description of securities: Ordinary Shares (H Shares and Domestic Shares)**

I.					
<b>Issues of shares</b> <i>(Notes 6 and 7)</i>	<b>No. of shares</b>	<b>Issued shares as a % of existing number of issued shares before relevant share issue</b> <i>(Notes 4, 6 and 7)</i>	<b>Issue price per share</b> <i>(Notes 1 and 7)</i>	<b>Closing market price per share of the immediately preceding business day</b> <i>(Note 5)</i>	<b>% discount/premium of issue price to market price</b> <i>(Note 7)</i>

Opening balance as at  
*(Note 2)*  
15 April 2020 (the last Next Day Disclosure Return published on 15 April 2020 pursuant to Rule 13.25A)

Share repurchased on 7 April 2020 but not yet cancelled	61,600 H shares	0.0816%			
Share repurchased on 8 April 2020 but not yet cancelled	20,000 H shares	0.0265%			
Share repurchased on 9 April 2020 but not yet cancelled	43,300 H shares	0.0574%			
Share repurchased on 14 April 2020 but not yet cancelled	63,900 H shares	0.0846%			
Share repurchased on 15 April 2020 but not yet cancelled	70,000 H shares	0.0927%			
Share repurchased on 16 April 2020 but not yet cancelled	40,000 H shares	0.0530%			
Closing balance as at (Note 8) 16 April 2020	75,500,000 ordinary shares including 55,260,000 domestic shares and 20,240,000 H shares				

We hereby confirm to the best knowledge, information and belief that, in relation to each issue of securities as set out in Section I, it has been duly authorized by the board of directors of the listed issuer and, insofar as applicable:

(Note 9)

- (i) all money due to the listed issuer in respect of the issue of securities has been received by it;
- (ii) all pre- \_\_\_\_\_ been fulfilled;
- (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
- (iv) all the securities of each c04 Tfn26e87.33 309.41 Tm0 g27eBT/F1 11.04 Tf1 1 11.04 Tf1 0 0 1 641.38 223.4()11(c042Te)-3(c)9(ur)7(i)-4(t)6(i)-4(es)-3lledpF1 112

*Notes to Section I:*

*1.*

## II.

## A. Purchase report

Trading date	Number of securities purchased	Method of purchase (Note)	Price per share or highest price paid \$	Lowest price paid \$	Total paid \$
16 April 2020	40,000	On the Exchange	HK\$18.0	HK\$18.0	HK\$720,000
	40,000				HK\$720,000
Total					

## B. Additional information for issuer whose primary listing is on the Exchange

1. Number of such securities purchased on the Exchange in the year to date (since ordinary resolution) (a) 544,900
2. % of number of shares in issue at time ordinary resolution passed acquired on the Exchange since date of resolution

( a ) x 100 )